Back to today’s briefing

Story perspectives

Study: Stopping GLP-1 Medications Raises Cardiovascular Risk

3/21/2026

50 4

Summary

Story summary

A BMJ Medicine study finds that stopping glucagon-like peptide-1 (GLP-1) medications such as Ozempic and Mounjaro increases cardiovascular risk.
The study analyzed 333,000 U.S. veterans and found heart benefits fade after cessation, with a 4% rise at six months and 22% at two years.
Researchers say GLP-1 treatment is needed to maintain benefits, noting many patients stop due to side effects or costs, and cessation can trigger a metabolic whiplash.

1 of 1

Story summary

A BMJ Medicine study finds that stopping glucagon-like peptide-1 (GLP-1) medications such as Ozempic and Mounjaro increases cardiovascular risk.
The study analyzed 333,000 U.S. veterans and found heart benefits fade after cessation, with a 4% rise at six months and 22% at two years.
Researchers say GLP-1 treatment is needed to maintain benefits, noting many patients stop due to side effects or costs, and cessation can trigger a metabolic whiplash.